

PRESS RELEASE
pursuant to article 17 of the AIM Italia Issuers Regulations

CO-OPTATION OF A NEW ADMINISTRATOR

Pisa, 9th May 2019 – Pharmanutra S.p.A. (“PHN” or the “Company”) announces that the Board of Directors, meeting today, having accepted the recent resignation of the board member Gianni Lazzarini on 16th April 2019 (as per the press release issued by PHN on the same date), has agreed, pursuant to article 2386 of Italian Civil Code and article 18 of the by-laws, the appointment by co-optation of Mr Giovanni Bucarelli, who will hold the appointment until the next PHN Assembly.

The new Director qualifies as a non-independent director and holds 18,125 ordinary shares in PHN, equal to 0.19% of the relative share capital.

The *curriculum vitae* of Mr Bucarelli is available on the Company’s website www.pharmanutra.it, Section “Corporate / Organi Sociali”.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 91 studies published involving more than 6000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524

investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.

Via dell’Annunciata 23/4
20121 Milan
Tel. +39 02 303431

ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708

Matteo Russo - Cristina Tronconi

Mob. +39 347 9834881 +39 346 0477901

mrusso@sprianocommunication.com

ctrone@sprianocommunication.com